U.S. markets closed
  • S&P Futures

    4,008.00
    +4.75 (+0.12%)
     
  • Dow Futures

    34,035.00
    +49.00 (+0.14%)
     
  • Nasdaq Futures

    11,814.00
    +8.25 (+0.07%)
     
  • Russell 2000 Futures

    1,844.30
    +2.40 (+0.13%)
     
  • Crude Oil

    77.43
    +0.50 (+0.65%)
     
  • Gold

    1,785.00
    +3.70 (+0.21%)
     
  • Silver

    22.53
    +0.12 (+0.53%)
     
  • EUR/USD

    1.0496
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    3.5990
    +0.0930 (+2.65%)
     
  • Vix

    20.75
    +1.69 (+8.87%)
     
  • GBP/USD

    1.2201
    +0.0007 (+0.06%)
     
  • USD/JPY

    136.8730
    +0.1880 (+0.14%)
     
  • BTC-USD

    16,998.48
    -216.01 (-1.25%)
     
  • CMC Crypto 200

    401.42
    -9.80 (-2.38%)
     
  • FTSE 100

    7,567.54
    +11.31 (+0.15%)
     
  • Nikkei 225

    27,908.09
    +87.69 (+0.32%)
     

Burberry Finance Chief Joins GSK As First Woman CFO

  • GSK plc (NYSE: GSK) has appointed Julie Brown as its first-ever female chief financial officer to succeed Iain Mackay.

  • Mackay, 60, will retire next year after serving as GSK's finance chief for nearly four years.

  • Julie will join GSK in April 2023 and will work with Iain to transition responsibilities, taking responsibility as CFO and as an Executive Director of GSK on 1 May 2023.

  • Ms. Brown currently serves as Chief Operating and Financial Officer at the luxury fashion brand Burberry Group plc (OTC: BURBY) (OTC: BBRYF). Julie has previously worked at AstraZeneca plc (NASDAQ: AZN) and Smith & Nephew plc (NYSE: SNN) as a non-executive director and Audit Chair of Roche Holdings AG.

  • Also Read: Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer.

  • Mackay's retirement, which has been in discussion for some time, comes after GSK's spin-off of its large consumer health business, Haleon Plc (NYSE: HLN), in July to focus on prescription drugs and vaccines.

  • Investors may be surprised to see Iain Mackay's retirement after only a few years in the role and the announcement coming only months after announcing the departure of head of R&D Hal Barron, Reuters quoted citing J.P. Morgan note.

  • "Post the recent separation of the consumer health business, there may have been a desire to increase Healthcare experience in GSK's management team," they wrote.

  • Price Action: GSK shares are down 0.75% at $29.14 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.